

Supporting information

High-fidelity correction of hereditary tyrosinemia in rats through Cas9-nickase-mediated genome editing

Yanjiao Shao^{1,†}, Liren Wang^{1,†}, Nana Guo¹, Shengfei Wang¹, Lei Yang¹, Yajing Li¹, Mingsong Wang¹, Shuming Yin¹, Honghui Han², Li Zeng^{1,2}, Ludi Zhang³, Lijian Hui³, Qiurong Ding⁴, Jiqin Zhang¹, Hongquan Geng⁵, Mingyao Liu^{1,6,*} and Dali Li^{1,*}

Table of Contents

Supplementary Figure 1 Indels generated by Cas9 or Cas9n in on-target sites in HEK293T cells

Supplementary Figure 2 Off-target events of Cas9 or Cas9n in HEK293T cells

Supplementary Figure 3 Indels generated by AdV-Cas9

Supplementary Table 1 Summary of animal groups

Supplementary Table 2 On-target /off-targt sites and primers used in this study

Supplementary Table 3 Off-target analyses by deep sequencing

Supplementary Sequence HDR template sequence

A EMX1-sgRNA1+Cas9

Target	PAM		
GAGTCCGAGCAGAAGAAGAGGG	GGG		
GGCCTGAGTCCGAGCAGAAGAAGAGGGCTCCCATCACATCAACCGGTGG		WT	
GGCCTGAGTCCGAGCAG---AAGAAGGGCTCCCATCACATCAACCGGTGG		-3bp	x 5
GGCCTGAGTCCGAGC-----AGAAGGGCTCCCATCACATCAACCGGTGG		-6bp	x 8
GGCCTGAGTCCGAGCAGAAGA-----GCTCCCATCACATCAACCGGTGG		-6bp	x 2
GGCCTGAGTCCG-----AGAAGGGCTCCCATCACATCAACCGGTGG		-9bp	x 1
GGCCTG-----AG---CAGAAGGGCTCCCATCACATCAACCGGTGG		-12bp	x 1
GGCCTGAG-----AGAAGGGCTCCCATCACATCAACCGGTGG		-13bp	x 1
GGCCT-----GAAGGGCTCCCATCACATCAACCGGTGG		-17bp	x 1
GGCCTGAGTCCGAGCAG---AAGAA-----CGGTGG		-22bp	x 1
-----GAAGGGCTCCCATCACATCAACCGGTGG		-26bp	x 1
-----TCCATCACATCAACCGGTGG		-100bp	x 1
GGCCTGAGTCCGAGCAGAAGAAAGAAGGGCTCCCATCACATCAACCGGTGG		+1bp	x 20
GGCCTGAGTCCGAGCAGAAGAA TTTACAGTCAAA TTAATTCTTAATTATCTCTCTAACAGCCTTGTATCCATCA		+36bp	x 1
CATCAACCGGTGG			

B EMX1-sgRNA1+Cas9n

Target	PAM		
GAGTCCGAGCAGAAGAAGAGGG	GGG		
GGCCTGAGTCCGAGCAGAAGAAGAGGGCTCCCATCACATCAACCGGTGG		WT	
GGCCTGAGTCCGA ACTT AAGAAGAGGGCTCCCATCACATCAACCGGTGG		x 1	

C VEGFA-sgRNA3+Cas9

Target	PAM		
GGGTGAGTGAGTGTGTGCGTGG	TGG		
TGTGTGGGTGAGTGTGTGTGCGTGTGGGGTTGAGGGCGTTGG		WT	
TGTGTGGGTGAGTGTGT-----GTGTGGGGTTGAGGGCGTTGG		-4bp	x 1
TGTGTGGGTGAGTGTGT-----GTGTGGGGTTGAGGGCGTTGG		-6bp	x 6
TGTGTGGGTGAGCGA-----GTGTGGGGTTGAGGGCGTTGG		-8bp	x 9
TGTGTGGGTGAGTGTGTG-----TGG		-21bp	x 1
TGTGTGGG-----TGAGGGCGTTGG		-24bp	x 1
TGTGTGGG-----TGAG T GCGTTGG		-24bp	x 1
TGTGTGGGTGAGTGTGTGTG CC TGTGGGGTTGGGGCGTTGG		+1bp	x 14
TGTGTGGGTGAGTGTGTGTG CC TGTGGGGTTGAGGGCGTTGG		+2bp	x 1
TGTGTGGGTGAGTGTGTGTG CT TGTGTGGGGTTGAGGGCGTTGG		+2bp	x 1
TGTGTGGGTGAGTGTGTGTG CCT TGTGTGGGGTTGAGGGCGTTGG		+3bp	x 1
TGTGTGGGTGAGTGTGTGTG CGACGCCTACCTGAACGCCG TGTGTGGGGTTGAGGGCGTTGG		+18bp	x 1
TGTGTGGGTGAGTGTGTGTG CGT CAGAGAC-18bp-TCACCGTGTGGGGTTGAGGGCGTTGG		+18bp	x 1
TGTGTGGGTGAGTGTGTGTG CTACGCC -108bp-TCGCCCTGTGTGGGGTTGAGGGCGTTGG		+108bp	x 1

Fig. S1. Indels generated by Cas9 or Cas9n in on-target sites in HEK293T cells. Indels detected in the on-target sites of (a) the EMX1 locus by Cas9, (b) the EMX1 locus by Cas9n, (c) the VEGFA locus by Cas9. The occurrence frequencies of each on-target indel clone are listed at the right.

A EMX1-OT+Cas9

Target	PAM	
GAGTTAGAGCAGAAGAAGGCC		
AGACAGATTGTCAGAGTTAGAGCAGAAGAAGGCCATGGAGTAAAGGC		WT
AGACAGATTGTCAGAGTTAGAGCAGAAGAAGCTAGAAAGGCATGGAGTAAAGGC		+4bp x 1

B VEGFA-OT-3-1+Cas9

Target	PAM	
ACTGAGTGAGTGTGTGTGGGG		
CGAGTGAGTGAGTGAGTGAGTGTGTGTGTGGGGGGGACTCGGCTT		WT
CGAGTGAGTGAGTGAGTGAGTGTG--TGTGGGGGGGACTCGGCTT		-2bp x 1
CGAGTGAGTGAGTGAGTGA--GTGTGTGTGGGGGGGACTCGGCTT		-2bp x 1
CGAGTGAGTGAGTGAGTGAGTG---TGTGGGGGGGACTCGGCTT		-4bp x 1
CGAGTGAGTGAGCGAGTGA-----GTGAGTGGGGGGGACTCGGCTT		-6bp x 2
CGAGTGAGTGAGTGAGTGA-----GTGGGGGGGACTCGGCTT		-8bp x 1
CGAGTGAGTGAGTGAGTGAGTGTGTGTGTGGGGGGGACTCGGCTT		+1bp x 26
CGAGTGAGTGAGTGAGTGAGTGTGTGTGGGGGGGACTCGGCTT		+1bp x 4
CGAGTGAGTGAGTGGTGTGTGTGTGTGGGGGGGACTCGGCTT		+1bp x 1
CGAGTGAGTGAGTGAGTGAGTGTGTGTGGCC-41bp-TACTGTGGGGGGGACTCGG		+41bp x 1
CGAGTGAGTGAGTGAGTGAGTGTGTGTTCAC-57bp-CCTGTGGGGGGGACTCGG		+57bp x 1

VEGFA-OT-3-2+Cas9

Target	PAM	
TGTGGGTGAGTGTGTGCGTGAGG		
TTTTATGTGTGGGTGAGTGTGTGCGTGAGGACATTTAAGATC		WT
TTTTATGTGTGGGTGAGTGTGTGCCGTGAGGACATTTAAGATC		+1bp x 4
TTTTATGTGTGGGTGAGTGTGTGACGTGAGGACATTTAAGATC		+2bp x 1
TTTTATGTGTGGGTGAGTGTGTGCTAGC-41bp-TCCGTGAGGACATTTAAGATC		+41bp x 1

VEGFA-OT-3-3+Cas9

Target	PAM	
GGTGAGTGAGTGCGTGCGGGTGG		
GGGAGTGGGTGAGTGAGTGAGTGCGTGCGGGTGGCGATGCAAG		WT
GGGAGTGGGTGAGTGAGTGCCGTGCGGGTGGCGATGCAAG		+1bp x 2
GGGAGTGGGTGAGTGAGTGCGGC-42bp-GGCGGTGCGGGTGGCGATGCAAG		+42bp x 1

C VEGFA-OT-3-1+Cas9n

Target	PAM	
AGTGAGTGAGTGTGTGTGGGG		
CGAGTGAGTGAGTGAGTGAGTGTGTGTGTGGGGGGGACTCGGCTT		WT
CGAGTGAGTGAGTGAGTGA--GTGTGTGTGGGGGGGACTCGGCTT		-2bp x 2
CGAGTGAGTAAGTGAGTGA--GTGTGTGTGGGGGGGACTCGGCTT		-2bp x 1
C----GAGTGAGTGAGTGAGTGTGTGTGTGGGGGGGACTCGGCTT		-4bp x 1
CGAGTGAGTGAGTGAGTG-G---GTGTGTGGGGGGGACTCGGCTT		-4bp x 1

Fig. S2. Off-target events of Cas9 or Cas9n in HEK293T cells. Indels detected in off-target sites of (a) the EMX1 locus by Cas9, (b) the VEGFA locus by Cas9 and (c) the VEGFA locus by Cas9n. The occurrence frequencies of each off-target indel are listed on the right. Base substitutions and insertions are labeled in red and green respectively. The occurrence frequencies of each off-target indel are listed on the right.

Fah locus +AdV-Cas9+AdV-HDR

```

TGTCACTCTTCTCCTAGCCAAAGCCACGGATTGGTGTGACCAGATCTTGGACCTGAGTGTCAATTAACAC FahΔ10/Δ10
TGTCACTCTTCTCCTAGCCAAAGCCACGGATTGGAGTGACCAGATCTTGGACCTGAGTGTCAATTAACAC +1bp
TGTCACTCTTCTCCTAGCCAAAGCCACGGATTGGTGTGACCAGA--TTGGACCTGAGTGTCAATTAACAC -2bp
TGTCACTCTTCTCCTAGCCAAAGCCACGGATTGGTGT-----GACCAAGAGTGTCAATTAACAC -12bp
TGTCACTCTTCTCCTAGCCAAAGCCACGGATTGG-----TGGACCTGAGTGTCAATTAACAC -13bp
TGTCACTCTTCTCCTAGCCAAAGCCACGGATTGGT-----CCTGAGTGTCAATTAACAC -16bp
TGTCACTCTTCTCCTAGCCAAAG-----CCTGAGTGTCAATTAACAC -28bp
TGTCACTCTTCTCCTAGCCAAAG-----C-----CAC -43bp
TGTCAC-----TGGACCTGAGTGTCAATTAACAC -41bp
TGTC-----AGTGTCAATTAACAC -50bp
TGTCACTCTTCTCCTAGCCAAAGCCACGGAAAGCTGA. (total 36bp) .ATTGGTGTGTCAATTAACAC +36bp

```

Fig. S3. Indels generated by AdV-Cas9. Sanger sequencing of 98 clones of the amplicons from the Adv-Cas9 treated rat revealed indels caused by Cas9-induced NHEJ. Indel sizes are listed on the right. The target sequence is indicated by the purple characters and the PAM sequence is in blue.

Table S1 Summary of animal groups

Injected adenovirus⁺	NTBC withdrawal	Surviving[§]/total animals
Cas9 + HDR template	Yes	3/4
Cas9n + HDR template	Yes	3/4
HDR template	Yes	0/4
PBS	Yes	0/4

⁺ Animals received total 2×10^{10} virus in 800 μ L PBS, including 1×10^{10} Cas9 (WT & nickase) and 1×10^{10} HDR template.

[§] NTBC free survival for at least 3 months.

Table S2 On-target /off-target sites and primers used in this study.

On-target and Off-target sites			
Target ID	Target sequence (5'-3')+pam	Target ID	Target sequence (5'-3')+pam
Fah ^{+/+} on-target	CCACGGATTGGTGTGGCCATCGG	Fah off 2	GGACTGGGGTAACCAGATCTTAG
Fah ^{Δ10/Δ10} on-target	GGATTGGTGTGACCAGATCTGG	Fah off 3	GGATGGGAGTGACCAGCTCTCAG
EMX1 on-target	GAGTCCGAGCAGAAGAAGAAGGG	Fah off 4	TCACTGGTTTGACCAGATCTGGG
EMX1 OTS	GAGTTAGAGCAGAAGAAGAAAGG	Fah off 5	GTA CTGGCATGACCAGATCTGGG
VEGFA on-target	GGT GAGT GAGT GTGTGCGTGTGG	Fah off 6	GGAATTGTGTGACCAGATCAGGG
VEGFA OTS-3-1	AGT GAGT GAGT GTGTGTGTGGGG	Fah off 7	GTCTGGTGTACCAGATCTGAG
VEGFA OTS-3-2	TGTGGGTGAGTGTGTGCGTGAGG	Fah off 8	TCAATGGTGTGGCCAGATCTCAG
VEGFA OTS-3-3	GGT GAGT GAGT GCGT GCGGGTGG	Fah off 9	GCCTCGGTGTGGCCAGATCTTGG
Fah off 1	GCAATGGTGGGACCAGATCTGGG	Fah off 10	GCCTGGGTGTGCCAGATCTGAG
Primers for PCR amplification			
Primer ID	Primer sequence	Primer ID	primer sequence
Fah PCR-F	CTGCTGCATTTAAGCTACCAC	Fah PCR-R	CATAGAAGCCAGGATGAGTGT
EMX1-F	CTCTTCCTGCCCTGCCATCC	EMX1-R	CCAGCCCATTGCTTGTCCCT
EMX1 OT-F	ATACAATGGGAAGGACAGC	EMX1 OT-R	TGTGGAGGCAATAAAGTGA
VEGFA 3-F	CAGATGGCACATTGTCAGAGGG	VEGFA 3-R	GAGGGAGCAGGAAAGTGAGGTTA
VEGFA OT-3-1-F	GTCGCCTGGATGCGGTTTC	VEGFA OT-3-1-R	CGTTATCGCTCATTTCCCTACGG
VEGFA OT-3-2-F	TGTATCCCTGGATTTTCGTAT	VEGFA OT-3-2-R	ATCTAATGTATGGCATGGTG
VEGFA OT-3-3-F	CTGCATTTCTTTGGCGTCTC	VEGFA OT-3-3-R	AGCACAGCCCTTACTCCTCC
rFah-OT1-F	ATTCAGAGTAGCATTCCCCACAGCAGC	rFah-OT1-R	TCTCGAGAGGGGAGTTTCAGGGACCAC
rFah-OT2-F	TATAGCCTAGAGTTCCTCATTTTGTCC	rFah-OT2-R	ATAGAGGCACTGTCTATTTATCCATTCG
rFah-OT3-F	CCTATCCTGAAGGAAGATGAGAAATGA	rFah-OT3-R	GGCTCTGACTGTTTTCCCTTAGAGTT
rFah-OT4-F	AGGCGAAGGGTCATCTCCTGCCTCTGC	rFah-OT4-R	TAATCTTAAGTGGGTAAGTCTAAGAATACA
rFah-OT5-F	CAGGACGTCTGTCATGGGACTCCTCGTC	rFah-OT5-R	GTA CTGACTACAGGCAAATCCC GTTC
rFah-OT6-F	ATTACTCGAAGAAAGCCAAGAATGACA	rFah-OT6-R	TCCGGAGAACCATCGACAGTTGAGGAC
rFah-OT7-F	CGCTCATTAGCAGGGCTCTGGTCAGGA	rFah-OT7-R	GAGATTCCGCCGAGGCTCAGGGAAACA
rFah-OT8-F	GAATTCGTTCCCAATGGGATAGTTAAG	rFah-OT8-R	CTGAAGCTTTTGCTCACTCAGTTCAC
rFah-OT9-F	TAATGCGCAGTTCCTACCCATAAGCCATC	rFah-OT9-R	CGGCTATGCCAAGACCTTAGACTCCCT
rFah-OT10-F	TCCGCGAAAGGAGGTTTGGGTAAGACA	rFah-OT10-R	AGCGATAGTTTGAAGCCTACATACGAG
IFN-β1 PCR-F	TGCCATTCAAGTGTATGCTCC	IFN-β1 PCR-R	CACCCAAGTCAATCTTTCCTCT
IL6 PCR-F	GTCTTCTGGAGTTCGGTTTC	IL6 PCR-R	GATGGTCTTGGTCCTTAGCC
IL10 PCR-F	CAGGACTTTAAGGGTTACTTGG	IL10 PCR-R	CATTCTTACCTGCTCCACT
β-actin PCR-F	GTACGCCAACACAGTGCTG	β-actin PCR-R	CGTCATACTCCTGCTTGCTG

Table S3 Off-target analyses by deep sequencing. Potential off-target sites predicted and scored by CRISPR Design for the on target sgRNA. Mismatched base pairs are labeled in red.

ID	Score	Spacer + PAM	Coordinate	Mismatches	Indel Adv-Cas9	Indel Adv-CAs9n	Indel PBS
Fah_sgRNA		GGATTGGTGTGACCAGATCTTGG					
Fah_off_1	2.5	GCAATGGTGGGACCAGATCTGGG	chr1:+283240856	3	0.0039	0.0039	0.0033
Fah_off_2	1.4	GGACTGGGGTAACCAGATCTTAG	chr19:-10419394	3	0.0019	0.0018	0.0016
Fah_off_3	1.1	GGATGGGAGTGACCAGCTCTCAG	chr8:-80645234	3	0.0013	0.0015	0.0012
Fah_off_4	0.9	TCACTGGTTTGACCAGATCTGGG	chr2:-137494772	4	0.001	0.001	0.0007
Fah_off_5	0.8	GTA CTGGCATGACCAGATCTGGG	chr1:-124157008	4	0.0025	0.0022	0.0021
Fah_off_6	0.8	GGAATTGTGTGACCAGATCAGGG	chr4:+228450195	3	0.001	0.0008	0.002
Fah_off_7	0.8	GTCC TGGTGTCAACCAGATCTGAG	chr15:-38501543	4	0.0017	0.0015	0.0015
Fah_off_8	0.7	TCAATGGTGTGGCCAGATCTCAG	chr7:+78415288	4	0.0013	0.0013	0.0009
Fah_off_9	0.7	GCCTCGGTGTGGCCAGATCTTGG	chr16:+7326951	4	0.0014	0.0014	0.0011
Fah_off_10	0.7	GCCTGGGTGTGCCAGATCTGAG	chr18:-30124498	4	0.002	0.0013	0.0015

Supplemental sequence HDR template sequence (5'-3')

ACACTATTATGCCACTATTACAGCATTGTGGAGATCTTGCTATCCCAGTGATTGTTGGGATACAT
AGGCATTAGAGCTGGGTAAGGCTACTCATAGCTCTCCTCGCTTGGCAACTTATAAAGCACTAA
AATGACTTAATACAATTGGGAGGCCCTTGTTACACATGACTAGGCAGGTAATGCCTGTGATCA
GGTAACAGATGACTTAGTGAGAGGTTCTTCTTGCCCTCAGCAAGGCATAGGATGATTGCCTC
TGAGTCTTTCCTGAACACCACCTGAGTGGACCCCCCAACTTAAGTAAATTCAGCTTGCTGATC
TTTGTGGCTGAATGAAGGCCCAGGGAATTACAGAGCTGAGAACACACAGGTTCTCCAGGGAA
GCTTCTAAGGTTTATGTGGCCTTAGTCTACCCCTAATCCCTGGGGGCTTCCAGGCAGCTACTTC
TCTTAGCCCCTGAAAGGAGCACTGGAGACAGACACAGCCAAGGATTCTACATCTCACCTCT
CCTGGATCTCCTAGAATATGGCAGAACTGCTGCTTCAGGTGCCAAGGAAGCCTAGCTTAGGAC
AGAGTTCAGGAGGTGAAATCTTCCAACATGCTCAGTGCTGTGAGGTCAGAGACCAGCCTTG
ACAAGATATTGGGCCTCTGTGTTCAATTTGAATCCATGCAGAGCTCTTACAGTGCATAAAAGAA
ATCCATTCATTTGGTCTGAGCACTGTGCCTTCTGCAGTTCCCTACGGCCTGAGCTCTGCTGCAT
TTAAGCTACCACAGAGCTGATACTCCAAGTTACTACATGTGTAACACTCACTGCTCTGCTTCAT
AAGAGAATGGCCCTGAGCAAAGCCCTGGGCCGAGCATGAAAAGAGGTTTCGGGTTCTTGGA
AGGTGATGAGCAACTCATAACTAGAGATCATGGCTCTGCTTTCTTTCTTGTCCCTGGATCCCCTC
TCAATGGAATCCATGAGTCCCTAAGTAACTGTGCTGTGACTGTCAGAACTGACTGTCACTCTT
CTCCTAGCCAAAGCCAAGGATCGGAGTCACGTGGACCTGAGTGTCAATAAACACCTCTTTACC
GGACCTGTCTCTCCAAACATCAGCATGTCTTCGATGAG GTAGGACATTGTGTCATGGACTGT
CTCTGTCTCACCACCTACTACAAATGACATAGCATCTTCATAGTCACCAGTTATTCCCGGATGA
GGAGGAGCTGTTCTGAGACACACAGGTGGCATGAGGTAGCCTCGACACCTTAGGGCAGCTTC
TCAATAGAATGTGAGCTCCTGAGTCCAGTGGATCTCTCCAAGTTGCCTATGAGGTGAGACTGT
TGTGTTAGCCTGGTTCCTTTATATAACAAGGATGTTTCATGCTTTGGTCTTTGGAGGCTCAGGAAA
ACCTTGAGAAAAGGAGCCATGAGCCTTGCAGTCTAGATTTTAGGGTAAAGCTTGAGACACTC
ATCCTGGCTTCTATGTTTCATGAATGATGACTGCCAGTACTTCAAGGGTACAGTCCTGGGGCAT
CCAACCTTGCTTGTGTGTCTGTGTAGGATGCCTACCCTGTCATCCAGGTATGCAGTTGTGCCTG
GGGCAGCCAGCTTGTCTACCTCGTCTGTGTGGGATGGATGTAACCTTC